AngioDynamics (NASDAQ:ANGO) Sets New 12-Month High – Time to Buy?

by · The Cerbat Gem

AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) shares hit a new 52-week high during trading on Monday . The stock traded as high as $13.99 and last traded at $13.32, with a volume of 2577 shares trading hands. The stock had previously closed at $13.14.

Analysts Set New Price Targets

A number of analysts have commented on the company. Canaccord Genuity Group lifted their target price on AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

Read Our Latest Analysis on ANGO

AngioDynamics Stock Up 0.8%

The company has a market cap of $545.45 million, a P/E ratio of -16.97 and a beta of 0.49. The company has a fifty day moving average of $12.19 and a 200 day moving average of $10.71.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last announced its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. The business had revenue of $75.71 million for the quarter, compared to analysts’ expectations of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The business’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same period last year, the firm posted ($0.11) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, research analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Insider Activity at AngioDynamics

In related news, SVP Lawrence T. Weiss acquired 10,000 shares of AngioDynamics stock in a transaction dated Tuesday, October 21st. The stock was purchased at an average cost of $11.81 per share, for a total transaction of $118,100.00. Following the purchase, the senior vice president directly owned 93,597 shares of the company’s stock, valued at approximately $1,105,380.57. This trade represents a 11.96% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO James C. Clemmer bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The stock was bought at an average cost of $11.15 per share, for a total transaction of $111,500.00. Following the completion of the acquisition, the chief executive officer owned 882,529 shares in the company, valued at $9,840,198.35. This trade represents a 1.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 20,890 shares of company stock valued at $239,532 over the last 90 days. 6.00% of the stock is currently owned by company insiders.

Institutional Trading of AngioDynamics

A number of hedge funds and other institutional investors have recently bought and sold shares of ANGO. Pier Capital LLC increased its holdings in AngioDynamics by 40.5% in the 2nd quarter. Pier Capital LLC now owns 694,235 shares of the medical instruments supplier’s stock worth $6,887,000 after acquiring an additional 200,244 shares in the last quarter. Stonepine Capital Management LLC bought a new position in shares of AngioDynamics in the second quarter worth approximately $765,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of AngioDynamics in the first quarter worth $939,000. Cubist Systematic Strategies LLC raised its position in shares of AngioDynamics by 71.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 232,473 shares of the medical instruments supplier’s stock valued at $2,183,000 after purchasing an additional 97,123 shares during the period. Finally, Divisadero Street Capital Management LP lifted its stake in shares of AngioDynamics by 253.7% during the 2nd quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier’s stock valued at $33,683,000 after buying an additional 2,435,365 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

Featured Articles